KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Assets Average: 2021-2025

Historic Assets Average for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $1.4 billion.

  • Recursion Pharmaceuticals' Assets Average rose 79.84% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 79.84%. This contributed to the annual value of $1.1 billion for FY2024, which is 55.15% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Assets Average stood at $1.4 billion for Q3 2025, which was up 3.62% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Assets Average registered a high of $1.4 billion during Q1 2025, and its lowest value of $285.3 million during Q1 2021.
  • Its 3-year average for Assets Average is $885.9 million, with a median of $666.9 million in 2024.
  • Its Assets Average has fluctuated over the past 5 years, first soared by 135.69% in 2022, then fell by 8.81% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Assets Average (Quarterly) stood at $634.5 million in 2021, then increased by 3.46% to $656.4 million in 2022, then decreased by 2.16% to $642.3 million in 2023, then soared by 69.33% to $1.1 billion in 2024, then soared by 79.84% to $1.4 billion in 2025.
  • Its Assets Average stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.4 billion for Q1 2025.